{
    "nct_id": "NCT01253499",
    "title": "A Phase 1 Study Consisting of a Double-Blind, Placebo Controlled Multiple Dose Study of TRx0037 in Healthy Elderly Volunteers",
    "status": "COMPLETED",
    "last_update_time": "2010-12-16",
    "description_brief": "The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of TRx0037 after multiple doses in elderly volunteers.",
    "description_detailed": "N/A",
    "phase": [
        "PHASE1"
    ],
    "study_type": "INTERVENTIONAL",
    "primary_purpose": "BASIC_SCIENCE",
    "results": null,
    "target_category": "disease-targeted small molecule",
    "drug": [
        "TRx0037 \u2014 small molecule (peptide-aggregation inhibitor) developed by TauRx Therapeutics"
    ],
    "placebo": [
        "placebo (trial used active placebo 2 mg and blank/placebo comparator)"
    ],
    "explanation_target": [
        "Reason: The described trial is a Phase 1, multiple-dose, double-blind, placebo-controlled safety/tolerability/pharmacokinetics study of TRx0037 in healthy elderly volunteers \u2014 this is documented in the trial registry entry. \ue200cite\ue202turn0search2\ue202turn0search0\ue201",
        "Act: TRx0037 is reported in drug/industry databases as a small-molecule agent with a mechanism described as a peptide-aggregation inhibitor (developed by TauRx) \u2014 i.e., aimed at inhibiting pathological protein aggregation (tau-related) rather than being a symptomatic cognitive enhancer. This supports classifying it as a disease-targeted small molecule. \ue200cite\ue202turn1search3\ue202turn1search4\ue201",
        "Additional trial detail (placebo): the registry entry notes use of an active placebo (2 mg) and a blank placebo as comparators in the multiple-dose study. \ue200cite\ue202turn0search2\ue201",
        "Reflect: Given TRx0037 is a small-molecule peptide-aggregation inhibitor aimed at Alzheimer pathology and the trial tests safety/PK (disease-modifying target), the correct category is 'disease-targeted small molecule'. No information suggests the compound is a biologic, a symptomatic cognitive enhancer, or an agent solely for neuropsychiatric symptoms. If you want, I can fetch the original sponsor/company materials or any chemistry/mechanism papers for TRx0037. \ue200cite\ue202turn1search3\ue202turn0search2\ue201"
    ],
    "agent_type": "B) Tau",
    "explanation_agent": [
        "Reason: TRx0037 is described in trial registries as a disease-targeted small molecule developed by TauRx and the company\u2019s program focuses on tau aggregation inhibitors (TAIs) intended to prevent or dissolve pathological tau aggregates \u2014 i.e., the intervention is directed at tau pathology rather than amyloid or symptomatic neurotransmission targets. \ue200cite\ue202turn0search5\ue202turn1search3\ue201",
        "Act: Independent drug- and pipeline-databases and drug pages list TRx-0037 with mechanism classed as a peptide-aggregation (tau aggregation) inhibitor, and the specific Phase 1 multiple-dose, double-blind placebo-controlled TRx0037 studies in healthy elderly volunteers are documented in clinical-trial records. These sources support classifying TRx0037 under the CADRO Tau category. \ue200cite\ue202turn1search1\ue202turn0search4\ue201",
        "Reflect: The available evidence consistently identifies TRx0037 as a small-molecule tau aggregation inhibitor (targeting tau pathology). There is no indication in the trial description that the compound primarily targets amyloid, inflammation, neurotransmitter receptors, or is a non-therapeutic diagnostic; therefore the most specific CADRO match is B) Tau. If further primary-source pharmacology (e.g., a published characterization of TRx0037 chemistry/mechanism) is required, I can retrieve and cite those papers. \ue200cite\ue202turn1search8\ue202turn1search0\ue201",
        "Web sources used: clinical-trial registry entries for the Phase 1 TRx0037 studies (trial details and status). \ue200cite\ue202turn0search4\ue202turn0search5\ue201",
        "Mechanism / drug info sources: TauRx company page on tau inhibition (describing Tau Aggregation Inhibitors), drug/pipeline databases and pages listing TRx-0037 as a peptide-aggregation (tau) inhibitor, and Alzforum/TauRx historical pages about TAIs. \ue200cite\ue202turn1search3\ue202turn1search1\ue202turn1search0\ue201"
    ]
}